Introduction {#acel12495-sec-0001}
============

Alzheimer\'s diseases (AD) is the most common cause of dementia in aged people and is characterized clinically by cognitive decline and pathologically by the accumulation of amyloid β‐protein (Aβ) and hyperphosphorylation of tau in the brain (Hoshino *et al*., [2007](#acel12495-bib-0016){ref-type="ref"}; Arnaud *et al*., [2009](#acel12495-bib-0003){ref-type="ref"}). Here, increases in the expression of several potentially toxic secretases, including BACE‐1, presenilin 1/2 (PS1/2), anterior pharynx‐defective (APH)**‐**1α/1β, nicastrin, and PEN2, result in the formation of Aβ plaques, synapse dysfunction or loss, neuronal loss, and diffuse brain atrophy, thereby leading to the decline of cognitive abilities (De Strooper, [2003](#acel12495-bib-0006){ref-type="ref"}). The γ‐secretases, such as APH‐1α and APH‐1β, are required for notch pathway signaling, for γ‐secretase cleavage of β‐APP, and for Aβ protein accumulation in *C. elegans* (Francis *et al*., [2002](#acel12495-bib-0009){ref-type="ref"}). Indeed, APH‐1 usually interacts with PEN‐2, nicastrin, and PS to generate an active form of the γ‐secretase complex, which is responsible for the cleavage of β‐APP and the deposition of Aβ (De Strooper, [2003](#acel12495-bib-0006){ref-type="ref"}). Once APH‐1 was found in *C. elegans* (Francis *et al*., [2002](#acel12495-bib-0009){ref-type="ref"}), the APH‐1 complex was then confirmed in several experimental models (Gu *et al*., [2003](#acel12495-bib-0011){ref-type="ref"}; Luo *et al*., [2003](#acel12495-bib-0025){ref-type="ref"}; Hansson *et al*., [2004](#acel12495-bib-0014){ref-type="ref"}). However, the regulatory mechanism of APH‐1α and APH‐1β are often overlooked during the course of AD progression.

To reveal the possible mechanism of APH‐1α and APH‐1β regulation, it is necessary to identify the molecular pathways that are responsible for the deposition of Aβ. Epidemiological and clinical data suggest that nonsteroidal anti‐inflammatory drugs (NSAIDs) are beneficial in the treatment and prevention of AD (Imbimbo *et al*., [2010](#acel12495-bib-0018){ref-type="ref"}). The protective effects of NSAIDs in AD are due to their anti‐inflammatory properties that inhibit cyclooxygenase‐2 (COX‐2) (McGeer, [2000](#acel12495-bib-0028){ref-type="ref"}; van Gool *et al*., [2003](#acel12495-bib-0010){ref-type="ref"}). As an important factor in inflammatory reactions of peripheral tissues, COX‐2 has a potential role in the pathogenesis of AD. This has been populously investigated through studies of its metabolic products, the prostaglandins (PGs), including PGE~2~, PGD~2~ \[and its dehydration end product 15‐deoxy‐Δ^12,14^‐PGJ~2~ (15d‐PGJ~2~)\], PGI~2~, PGF~2α,~ and TXA~2~ (Akarasereenont *et al*., [1999](#acel12495-bib-0001){ref-type="ref"}). For example, PGE~2~ treatment increases the ratio of Aβ~1--42~/Aβ~1--40~ production in SH‐SY5Y cells and APP23 transgenic mice (Hoshino *et al*., [2007](#acel12495-bib-0016){ref-type="ref"}, [2009](#acel12495-bib-0017){ref-type="ref"}). In line with these observations, PGE~2~ was further verified to stimulate the production of Aβ~1--42~ alone in C57BL/6 mice (Echeverria *et al*., [2005](#acel12495-bib-0007){ref-type="ref"}). In addition to PGE~2~, PGD~2~ shows positive effects on stimulating the production of Aβ~1--42~ in primary mouse microglia and neuronal cells (Bate *et al*., [2006](#acel12495-bib-0004){ref-type="ref"}). As expected, 15d‐PGJ~2~ is also able to increase fibrillar Aβ in rat cortical neurons (Takata *et al*., [2003](#acel12495-bib-0042){ref-type="ref"}; Yamamoto *et al*., [2011](#acel12495-bib-0052){ref-type="ref"}) while PGF~2α~ has been shown to be involved in Aβ production in microglia cells (Zhuang *et al*., [2013](#acel12495-bib-0056){ref-type="ref"}). However, the effects of PGI~2~ on the production of Aβ are not well studied.

In this study, an intracellular signaling pathway by which PGI~2~ regulates the expression of APH‐1α/1β has been proposed to contribute to the deposition of Aβ. Specifically, PGI~2~ treatment increases the expression of APH‐1α/1β via the PKA/CREB and JNK/c‐Jun activation pathways in SH‐SY5Y cells, which facilitates the synthesis of Aβ in neuron cells. More importantly, in AD, the Aβ oligomers were localized to the CSF microenvironment, which contributes to the expression of APH‐1α/1β. Reconstructing the signaling network that regulates PGI~2~‐mediated APH‐1α/1β expression in neuron cells will facilitate the development of strategies to combat AD.

Results {#acel12495-sec-0002}
=======

APH‐1α/1β is highly induced in APP/PS1 transgenic mice {#acel12495-sec-0003}
------------------------------------------------------

Due to previous reports of a pivotal role of APH‐1α/1β in the pathogenesis of AD (Mrak & Griffin, [2001](#acel12495-bib-0031){ref-type="ref"}; De Strooper, [2003](#acel12495-bib-0006){ref-type="ref"}), we evaluated the expression levels of APH‐1α/1β in AD brains. As shown in Fig. [1](#acel12495-fig-0001){ref-type="fig"}a, the immunoreactivity of APH‐1α/1β and Aβ was highly induced at the patients with AD. In accordance with this observation, the mRNA and protein expression levels of APH‐1α/1β were elevated at the patients with AD (Fig. [1](#acel12495-fig-0001){ref-type="fig"}b). Due to the limited accessibility of human AD samples, we performed similar experiments in APP/PS1 mice. The results demonstrated that APH‐1α/1β immunostaining was markedly increased in the cerebral cortex as well as in the dentate gyrus region of the hippocampus of APP/PS1 transgenic mice at 6 months of age, when compared to the WT C57BL/6 mice (Fig. [1](#acel12495-fig-0001){ref-type="fig"}d). In accordance with our immunostaining observations, the mRNA and protein expression of APH‐1α/1β was upregulated in the cerebral cortex and hippocampus of APP/PS1 mice (Fig. [1](#acel12495-fig-0001){ref-type="fig"}c,e). When considered together, these results clearly demonstrate that APH‐1α/1β levels were increased in APP/PS1 transgenic mice. These data agree with previous reports (De Strooper, [2003](#acel12495-bib-0006){ref-type="ref"}), suggesting that APH‐1α/1β are possibly involved in aggravating AD.

![The expression of APH‐1α/1β is markedly increased in patients with AD and APP/PS1 transgenic mice at 6 months of age when compared with control subjects. The tissue blocks of human brains of AD were collected by the New York Brain Bank at Columbia University and Fengtian Hospital of China. Free‐floating slices (40 μm) were prepared using a cryostat (a, b). In selected experiments, the brains of APP/PS1 transgenic mice at 6 months of age were collected following anesthesia and perfusion (c--f). The immunoreactivity of APH‐1 or Aβ~1--42~ was determined by IHC using an anti‐APH‐1 or Aβ~1--42~ antibody (a, d). APH‐1α/1β mRNA and protein levels were determined by qRT--PCR and immunoblotting (*n* = 3 for human sample, *n* = 6 for mouse samples) (b, c, e). The production of PGI ~2~ in the brains of APP/PS1 transgenic or of WT mice was determined by PGI ~2~ determination kits (f). The data represent the means ± S. E. of at least three independent experiments. \**P \< 0.05* with respect to the WT or normal human controls.](ACEL-15-861-g001){#acel12495-fig-0001}

Elevation of PGI~2~ accelerates the synthesis of APH‐1α/1β in APP/PS1 transgenic mice {#acel12495-sec-0004}
-------------------------------------------------------------------------------------

We next sought to elucidate the mechanism by which APH‐1α/1β are upregulated in an AD mouse model. Because evidence suggests that PGI~2~ is a potential mediator of neuroinflammation (Ford‐Hutchinson *et al*., [1978](#acel12495-bib-0008){ref-type="ref"}; Honda *et al*., [2005](#acel12495-bib-0015){ref-type="ref"}; Pulichino *et al*., [2006](#acel12495-bib-0036){ref-type="ref"}), we sought to determine the concentration of PGI~2~ in APP/PS1 transgenic mice at 6 months of age. As shown in Fig. [1](#acel12495-fig-0001){ref-type="fig"}f, the synthesis of PGI~2~ was markedly increased in APP/PS1 transgenic mice. To know the roles of PGI~2~ in AD development, we first screened the effects of PGI~2~ on the expression of α‐, β‐ or γ‐secretases. The results demonstrated that PGI~2~ treatment concurrently downregulated the expression of ADAM‐10 and upregulated the expression of BACE‐1, PS2, and APH‐1α/1β in n2a cells (Table [1](#acel12495-tbl-0001){ref-type="table-wrap"}). To further understand the possible role of PGI~2~ in AD, we then injected (i.c.v.) PGI~2~ (2 μg/5 μL) or incubated brain slices from WT C57BL/6 mice with PGI~2~ (10 μ[m]{.smallcaps}) for 24 h. IHC staining indicated that APH‐1α/1β expression was induced in both the cerebral cortex and the DG region of APP/PS1 transgenic mice (Fig. [2](#acel12495-fig-0002){ref-type="fig"}a,b). In addition, these observations were verified by qRT--PCR and Western blots (Fig. [2](#acel12495-fig-0002){ref-type="fig"}c,d). To identify the role of PGI~2~ in inducing the expression of APH‐1α/1β, we conducted live animal and two‐photon imaging experiments, as described in the 'Materials and Methods'. The results revealed that PGI~2~ (2 μg/5 μL) injection (i.c.v.) into the ventricles of WT C57BL/6 mice increased the luciferase activity of the APH‐1α/1β promoters at 12 h following injection. This activity was maximal at 24 h following injection (Fig. [2](#acel12495-fig-0002){ref-type="fig"}e). Of note, PBS (−) injection (i.c.v.) does not alter the activity of APH‐1α and APH‐1β promoters (data not shown). Two‐photon imaging results reinforced the notion that PGI~2~ (2 μg/5 μL) injection (i.c.v.) increased the immunofluorescence of APH‐1α/1β in the cerebral cortex of WT C57BL/6 mice (Fig. [2](#acel12495-fig-0002){ref-type="fig"}f). Accordingly, we then treated the SH‐SY5Y and n2a neuronal cells with PGI~2~ (10 μ[m]{.smallcaps}) for 48 h. Our data demonstrated that PGI~2~ treatment clearly increases the expression of APH‐1α/1β in human or mouse neurons (Fig. [2](#acel12495-fig-0002){ref-type="fig"}g,h). These results were supported by the immunostaining experiments, and the images obtained using Leica confocal microscopy (Fig. [2](#acel12495-fig-0002){ref-type="fig"}i,j). Collectively, our data clearly support the fact that PGI~2~ elevation increases the synthesis of APH‐1α/1β *in vitro* and *in vivo*.

###### 

The effects of PGI~2~ on the expression of α‐, β‐, or γ‐secretases in n2a cells

  Gene Name   Control   PGI~2~ (10 μ[m]{.smallcaps})
  ----------- --------- ------------------------------
  ADAM‐10     1         0.59
  BACE‐1      1         4.59
  PS1         1         0.99
  PS2         1         1.92
  APH‐lα      1         3.25
  APH‐lβ      1         1.99
  Nicastrin   1         0.94
  PEN2        1         1.08
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![Involvement of PGI ~2~ in inducing the expression of APH‐1α/1β. (a, c, d) The WT C57BL/6 mice at 6 months of age were injected (i.c.v.) with PGI ~2~ (2 μg/5 μL), and the brains were then collected and sectioned after 24 h. The immunoreactivity of APH‐1 was determined by immunohistochemistry using an anti‐APH‐1 antibody (a). APH‐1α/1β mRNA and protein levels were determined by qRT--PCR and Western blots, respectively (*n* = 8) (c, d). (b) The brains of WT C57BL/6 mice at 6 months of age were harvested and freshly sectioned (400 μm) before treatment with PGI ~2~ (10 μ[m]{.smallcaps}) for 24 h. The slices were immunostained with APH‐1 antibody. (e) PGI ~2~ (2 μg/5 μL) or vehicle (PBS) was injected (i.c.v.) into one side of a cerebral ventricle in the absence or presence of preseeded n2a cells that were transfected with APH‐1α/β promoters in the other side of cerebral ventricle (*n* = 6). Luciferase activities from the different groups of mice were measured using a live animal imaging system. (f) The left cerebral ventricle was injected with PGI ~2~ (2 μg/5 μL) or vehicle (PBS) solution before staining with an APH‐1 antibody and scanning using two‐photon microscopy (*n* = 6). (g--j) SH‐SY5Y or n2a cells were treated with PGI ~2~ (10 μ[m]{.smallcaps}) for 48 h. APH‐1α/1β mRNA and protein levels were determined by qRT--PCR and Western blots, respectively (g, h). The immunofluorescence of APH‐1 was determined by immunohistochemistry using a primary rabbit APH‐1 antibody and secondary Alexa Fluor 488‐labeled goat anti‐rabbit IgG (i, j). The data represent the means ± SE of three independent experiments. \**P \< 0.05* with respect to the vehicle‐treated control.](ACEL-15-861-g002){#acel12495-fig-0002}

PGI~2~ inhibition impaired the expression of APH‐1α/1β following intranasal administration of NS398 in APP/PS1 transgenic mice {#acel12495-sec-0005}
------------------------------------------------------------------------------------------------------------------------------

Because PGI~2~ is an important metabolic product of COX‐2, we treated APP/PS1 transgenic mice with a COX‐2‐specific inhibitor, NS398 (50 μg kg^−1^ day^−1^), for 5 months. Our results revealed that PGI~2~ was significantly suppressed by NS398 (50 μg kg^−1^ day^−1^) administration in APP/PS1 transgenic mice (Fig. [3](#acel12495-fig-0003){ref-type="fig"}a). More interestingly, the inhibition of PGI~2~ by NS398 resulted in a decrease in the levels of APH‐1α/1β in APP/PS1 transgenic mice by IHC staining (Fig. [3](#acel12495-fig-0003){ref-type="fig"}c). Similar results were verified by qRT--PCR or Western blot experiments (Fig. [3](#acel12495-fig-0003){ref-type="fig"}e,f). Of note, NS398 treatment does not affect the body weight of mice and induce wound healing to the mice as previously indicated (Wang *et al*., [2011a](#acel12495-bib-0045){ref-type="ref"}). We then injected APP/PS1 transgenic mice with NS398 (2 μg/5 μL) for 24 h. The results demonstrated that the injection (i.c.v.) of NS398 (2 μg/5 μL) shows a suppressive effect on the production of PGI~2~ in APP/PS1 transgenic mice (Fig. [3](#acel12495-fig-0003){ref-type="fig"}b). Of note, our results reinforce the hypothesis that NS398 treatment (2 μg/5 μL) suppressed the expression of APH‐1α/1β (Fig. [3](#acel12495-fig-0003){ref-type="fig"}d,g,h) by inhibiting the production of PGI~2~. In addition, the production of sAPPα was restored to the control level (i.e. the basal level of WT mice), whereas the increased production of sAPPβ was attenuated to the basal level of WT mice following intranasal administration of NS398 treatment for 5 months in APP/PS1 mice (Fig. [3](#acel12495-fig-0003){ref-type="fig"}i,j). Intranasal administration of NS398 also decreased the production of Aβ~1--42~ in APP/PS1 mice (Fig. [3](#acel12495-fig-0003){ref-type="fig"}i,j), which potentially decelerates the pathogenesis of AD. To further verify the role of NS398 in suppressing the expression of APH‐1α/1β, we performed intracerebroventricular injections of the inhibitor. Similar to nasal administration, NS398 injection (i.c.v., 2 μg/5 μL) reversed the concurrent downregulation of sAPPα and upregulation of sAPPβ in APP/PS1 mice (Fig. [3](#acel12495-fig-0003){ref-type="fig"}k,l). Therefore, our results concretely support the hypothesis that NS398 has the ability to suppress the expression of APH‐1α/1β by decreasing the production of PGI~2~ in APP/PS1 transgenic mice.

![NS398 administration decreases the expression of APH‐1α/1β via inhibiting the production of PGI ~2~ in APP/PS1 transgenic mice. The APP/PS1 transgenic mice at 1 month of age received NS398 (50 μg kg^−1^ day^−1^) for 5 months before harvesting brain slices (*n* = 3) (a, c, e, f, i, j). In selected experiments, the APP/PS1 transgenic mice at the 6 months of age were injected (i.c.v.) with NS398 (2 μg/5 μL). The brains were then collected and sectioned after 24 h (*n* = 8) (b, d, g, h, k, l). The production of PGI ~2~ was determined by PGI ~2~ enzyme immunoassay kits (a, b). The immunoreactivity of APH‐1 was determined by immunohistochemistry using an anti‐APH‐1 antibody (c, d). APH‐1α/1β mRNA and protein expression levels were determined by qRT--PCR and Western blots, respectively (e--h). The production of sAPPα and sAPPβ was determined by Western blots (i--l). The production of Aβ~1--42~ was determined by Aβ~1--42~ ELISA kits (i‐l). The data represent the means ± SE of three independent experiments. \**P \< 0.05* with respect to WT mice. ^\#^ *P \< 0.05* compared to APP/PS1 transgenic mice.](ACEL-15-861-g003){#acel12495-fig-0003}

Critical role of PKA/CREB and JNK/c‐Jun signaling pathways in mediating PGI~2~‐induced APH‐1α/1β expression in n2a cells {#acel12495-sec-0006}
------------------------------------------------------------------------------------------------------------------------

We next aimed to elucidate the signaling pathways of APH‐1α/1β synthesis in PGI~2~‐treated n2a cells. First, 48 h of PGI~2~ (10 μ[m]{.smallcaps}) treatment activated PKA/CREB and JNK/c‐Jun signaling pathways by the phosphorylation of CREB and c‐Jun (Fig. [4](#acel12495-fig-0004){ref-type="fig"}a--c), which resulted in the synthesis of APH‐1α and APH‐1β in n2a cells (Fig. [4](#acel12495-fig-0004){ref-type="fig"}a,c). To further elucidate the role of PKA/CREB and JNK/c‐Jun signaling pathways in regulating the expression of APH‐1α/1β, we treated n2a cells with the PKA pharmacological inhibitor H89 (1 μ[m]{.smallcaps}) or JNK‐specific inhibitor SP600125 (10 μ[m]{.smallcaps}). Treatment of n2a cells with H89 (1 μ[m]{.smallcaps}) or SP600125 (10 μ[m]{.smallcaps}) not only suppressed the phosphorylation of CREB and c‐Jun (Fig. [4](#acel12495-fig-0004){ref-type="fig"}a--c) but also reversed the synthesis of APH‐1α/1β in PGI~2~‐treated n2a cells (Fig. [4](#acel12495-fig-0004){ref-type="fig"}a,c).

![PGI ~2~ elevation stimulates the expression of APH‐1α/1β via the PKA/CREB and JNK/c‐Jun signaling pathways in cultured neuronal cells. n2a cells were treated with PGI ~2~ (10 μ[m]{.smallcaps}) in the absence or presence of H89 (1 μ[m]{.smallcaps}) (a, b, f) or SP600125 (5 μ[m]{.smallcaps}) (c, g) cells for 48 h. In distinct experiments, n2a cells were transfected with CREB (d) or c‐Jun siRNA (e) before treating the cells with PGI ~2~ (10 μ[m]{.smallcaps}) for 48 h. APH‐1α/1β mRNA and protein levels were determined by qRT--PCR and Western blots, respectively (a, c--e). Phosphorylated CREB and c‐Jun as well as total CREB and c‐Jun were detected by immunoblotting using specific antibodies (a--e). The production of sAPPα and sAPPβ was determined by Western blots (f, g). The production of Aβ~1--42~ was determined by Aβ~1--42~ ELISA kits (f, g). The data represent the means ± SE of three independent experiments. \**P \< 0.05* with respect to the vehicle‐treated or vector‐transfected control. ^\#^ *P \< 0.05* compared to PGI ~2~‐treated alone.](ACEL-15-861-g004){#acel12495-fig-0004}

To verify these observations and to account for the nonspecificity of the pharmacological inhibitors, we transfected n2a cells with siRNAs that were specific for interfering with the expression of CREB or c‐Jun prior to incubating them with PGI~2~ (10 μ[m]{.smallcaps}). As shown in Fig. [4](#acel12495-fig-0004){ref-type="fig"}d and e, CREB and c‐Jun knockdown efficiently decreased the protein levels of CREB and c‐Jun. As a consequence, the knockdown of CREB or c‐Jun inhibited the effects of PGI~2~ on inducing the synthesis of APH‐1α/1β in n2a cells (Fig. [4](#acel12495-fig-0004){ref-type="fig"}d,e). In addition, inhibiting the signaling pathways of PKA/CREB and JNK/c‐Jun concurrently results in the restoration of the production of sAPPα and a decrease in the production of sAPPβ to the basal level in PGI~2~‐treated n2a cells (Fig. [4](#acel12495-fig-0004){ref-type="fig"}f,g). More importantly, inhibiting the activity of the PKA/CREB or the JNK/c‐Jun signaling pathways resulted in the attenuation of Aβ~1--42~ formation in PGI~2~‐activated n2a cells (Fig. [4](#acel12495-fig-0004){ref-type="fig"}f,g). Therefore, these observations support the hypothesis that PKA/CREB and JNK/c‐Jun signaling pathways are important in mediating PGI~2~‐induced APH‐1α/1β expression, which results in Aβ~1--42~ deposition in neuron cells.

Aβ oligomers in the CSF of APP/PS1 mice have the ability to stimulate the expression of APH‐1α/1β {#acel12495-sec-0007}
-------------------------------------------------------------------------------------------------

Because NS398 incubation decreases the expression of APH‐1α/1β and Aβ~1--42~ deposition by decreasing the production of PGI~2~ *in vitro* and *in vivo*, we next examined the potential contribution of Aβ~1--42~ to the pathogenesis of AD. We conducted experiments to determine whether Aβ~1--42~ is confined to microenvironments that are related to AD in APP/PS1 transgenic mice. In brief, the cerebrospinal fluid (CSF) of APP/PS1 transgenic mice was injected into WT C57BL/6 mice in the absence or presence of Aβ antibody for 2 weeks prior to sacrifice. When compared to control animals, the expression of APH‐1α/1β in both the cerebral cortex and hippocampus was markedly increased by the injection (i.c.v.) of APP/PS1 CSF (Fig. [5](#acel12495-fig-0005){ref-type="fig"}a--c). In addition, the elevated induction of APH‐1α/1β was suppressed by the injection (i.c.v.) of the Aβ antibody (1 μg/5 μL) (Fig. [5](#acel12495-fig-0005){ref-type="fig"}a--c). Therefore, these observations demonstrate that the confinement of the secreted form of Aβ~1--42~ to AD‐related microenvironments might induce the expression of APH‐1α/1β in a PGI~2~‐dependent manner.

![NS398 treatment diminished the effects of Aβ oligomers on inducing the expression of APH‐1α/1β. Cerebrospinal fluid (CSF) was obtained from APP/PS1 transgenic mice, which was then injected (i.c.v.), in the absence or presence of Aβ antibody (1 μg/5 μL), into C57BL/6 mice for 2 weeks before sacrifice (a--c). In selected experiments, the WT C57BL/6 mice at 6 months of age were injected (i.c.v.) with Aβ oligomers (2 μg/5 μL) in the absence or presence of NS398 (2 μg/5 μL). The brains were then collected and sectioned after 24 h (d--f). In separate experiments, the brains of WT C57BL/6 mice at 6 months of age were harvested and freshly sectioned (400 μm) before treatment with Aβ (1 μ[μ]{.smallcaps}) in the absence or presence of NS398 (10 μ[m]{.smallcaps}) for 24 h (g). In distinct experiments, SH‐SY5Y or n2a cells were treated with Aβ (1 μ[m]{.smallcaps}) in the absence or presence of NS398 (10 μ[m]{.smallcaps}) for 24 h (h, i). The immunoreactivity of APH‐1 was determined by IHC using an anti‐APH‐1 antibody (a, d, g). APH‐1α/1β mRNA and protein expression was determined by qRT--PCR and Western blots, respectively (*n* = 8) (b, c, e, f, h, i). The data represent the means ± SE of three independent experiments. \**P \< 0.05* with respect to vehicle‐treated controls. ^\#^ *P \< 0.05* compared to APP/PS1 CSF‐ or Aβ‐treated alone.](ACEL-15-861-g005){#acel12495-fig-0005}

To confirm these observations, we performed experiments to directly evaluate the involvement of Aβ~1--42~ oligomers in the progression of AD. Aβ oligomer (2 μg/5 μL) injection (i.c.v.) clearly increases the expression of APH‐1α/1β in both the cerebral cortex and hippocampus of WT C57BL/6 mice (Fig. [5](#acel12495-fig-0005){ref-type="fig"}d--f). The upregulation of APH‐1α/1β was further suppressed by NS398 (2 μg/5 μL) injection (i.c.v.) in Aβ~1--42~‐stimulated C57BL/6 mice (Fig. [5](#acel12495-fig-0005){ref-type="fig"}d--f). These *in vivo* observations were reinforced by *in vitro* experiments that demonstrated that Aβ (1 μ[m]{.smallcaps}) treatment stimulates the expression of APH‐1α/1β in neuron cells by organotypic slice or cell culture (Fig. [5](#acel12495-fig-0005){ref-type="fig"}g--i). Thus, Aβ~1--42~ oligomers are critical for worsening AD.

Discussion {#acel12495-sec-0008}
==========

β‐amyloid protein (Aβ) deposition and hyperphosphorylation of tau are pathological characteristics of AD (1). As the role of PGI~2~ in AD development is presently unknown, we designed a study to identify the aggravating effects of PGI~2~ on AD. The major findings of this study are as follows: (i) APH‐1α/1β expression was markedly upregulated during the course of AD development; (ii) the accumulation of PGI~2~ in neuron cells induced the mRNA and protein expression of APH‐1α/1β in APP/PS1 mice; (iii) the PKA/CREB and JNK/c‐Jun signaling pathways are critical for mediating the effects of PGI~2~ on stimulating the expression of APH‐1α/1β, which is critical for γ‐cleavage of β‐APP and producing Aβ~1--42~; and (iv) Aβ~1--42~ oligomers in the CSF of APP/PS1 mice are responsible for augmenting the activity APH‐1α/1β, which potentially aggravates the pathogenesis of AD (Fig. [6](#acel12495-fig-0006){ref-type="fig"}).

![Proposed cascade of the signaling events regulating the pathogenesis of AD by PGI ~2~. In detail, elevated levels of PGI ~2~ in APP/PS1 transgenic mice will enhance the expression of APP‐1α/1β via the PKA/CREB and JNK/c‐Jun pathways in neuron cells of APP/PS1 transgenic mice, which in turn aggravates the pathogenesis of AD. Moreover, the highly secreted Aβ oligomers from neuron cells are able to reciprocally regulate the expression of APH‐1α/1β, which further aggravate the pathogenesis of AD *in vivo*. PGI ~2~, a metabolic product of COX‐2, inhibition by NS398 administration reversed the effects of APP/PS1 overexpression in stimulating the expression of APH‐1α/1β, which potentially contributes to improvement in study ability and decline in cognitive ability in APP/PS1 transgenic mice.](ACEL-15-861-g006){#acel12495-fig-0006}

Substantial evidence indicates that prostaglandins, such as PGE~2~ and 15d‐PGJ~2~, are important for Aβ deposition and tau tangling, which contribute to the role of COX‐2 in the pathophysiology of AD (Hoshino *et al*., [2007](#acel12495-bib-0016){ref-type="ref"}; Arnaud *et al*., [2009](#acel12495-bib-0003){ref-type="ref"}). However, knowledge concerning the specific function of PGI~2~ in the human brain is limited. Indeed, the assumption that PGI~2~ is synthesized in brain tissue *in vivo* is based on observations in primary culture of astrocytes and meningeal cells (Murphy *et al*., [1985](#acel12495-bib-0032){ref-type="ref"}) as well as of the expression of PGI~2~ receptor (PI) in the rodent brain (Oida *et al*., [1995](#acel12495-bib-0034){ref-type="ref"}; Takechi *et al*., [1996](#acel12495-bib-0043){ref-type="ref"}). Siegle *et al*. (Siegle *et al*., [2000](#acel12495-bib-0040){ref-type="ref"}) supported this hypothesis by demonstrating, via IHC and *in situ* hybridization, that glia and neuron cells in the human brain express PGI~2~ synthase (PGIS). Moreover, the expression of PGIS in the human brain was supported by the detection of 6‐keto‐PGF1α, a stable degradation product of PGI~2~, in human brain homogenates by enzyme immunoassay kits (Siegle *et al*., [2000](#acel12495-bib-0040){ref-type="ref"}). Our data agree with this prior work (Siegle *et al*., [2000](#acel12495-bib-0040){ref-type="ref"}) by demonstrating the presence of PGI~2~ in the brains of C57BL/6 mice. PGI~2~ production was elevated in the brain of APP/PS1 transgenic mice when compared with that of the WT control. PGI~2~ synthesis may result from COX‐2 upregulation in APP/PS1 transgenic mice (data not shown). Yosojima *et al*. (Yasojima *et al*., [1999](#acel12495-bib-0053){ref-type="ref"}) reported that COX‐2 was substantially upregulated in the affected areas of AD brains. In addition, COX‐2 is responsible for the systemic synthesis of PGI~2~ (McAdam *et al*., [1999](#acel12495-bib-0027){ref-type="ref"}). Therefore, PGI~2~ synthesis was markedly increased during the course of AD progression.

PGI~2~ elevation was initially found to be involved in the actions of inflammation (Ford‐Hutchinson *et al*., [1978](#acel12495-bib-0008){ref-type="ref"}). In addition, treatment with PGI~2~ analogs, including iloprost and treprostinil, suppressed TNF‐α expression in human myeloid dendritic cells (Kuo *et al*., [2012](#acel12495-bib-0022){ref-type="ref"}). Schuh *et al*. ([2014](#acel12495-bib-0038){ref-type="ref"}) also reported that the early induction of PGI~2~ at the site of traumatic injury resulted in the aggregation of IL‐1β‐expressing macrophages as a critical reason for neuropathic pain. Although the effects of these cytokines on Aβ production are still in debating, these prior works have indicated that PGI~2~ might play its roles in AD via inducing the production of cytokines. Apart from the inflammatory effects of PGI~2~, the ability of neuron cells to express elevated amounts of PGI~2~ in APP/PS1 transgenic mice suggests that PGI~2~ may be important to the pathogenesis of AD. Because there is no report that demonstrates the functional significance of PGI~2~ in regulating Aβ deposition, we assayed for the synthesis of α‐, β‐, and γ‐secretases in PGI~2~‐treated neuronal cells. The results demonstrated that the expression of BACE‐1 and APH‐1α/1β was upregulated while ADAM‐10 expression was downregulated in PGI~2~‐treated n2a cells. Therefore, PGI~2~ elevation could possibly accelerate the deposition of Aβ~1--42~ by decreasing the expression of α‐secretase and increasing the expression of β‐ and γ‐secretases. As the roles of ADAM‐10 and BACE‐1 in Aβ deposition have been thoroughly investigated (Niemitz, [2013](#acel12495-bib-0033){ref-type="ref"}), we sought to determine the effects of PGI~2~ in stimulating the expression of APH‐1α/1β. Although there are no reports that demonstrate the effects of PGI~2~ in inducing the expression of APH‐1α/1β, APH‐1α/1β are required for notch pathway signaling, for γ‐secretase cleavage of β‐APP, and for Aβ protein accumulation in *C. elegans* (Francis *et al*., [2002](#acel12495-bib-0009){ref-type="ref"}). Indeed, APH‐1 often combines with PEN‐2, nicastrin, and PS to generate an active form of γ‐secretase complex, which is responsible for the cleavage of β‐APP and for the deposition of Aβ (De Strooper, [2003](#acel12495-bib-0006){ref-type="ref"}). Once APH‐1 was found in *C. elegans* (Francis *et al*., [2002](#acel12495-bib-0009){ref-type="ref"}), the APH‐1 complex was confirmed in several experimental models (Gu *et al*., [2003](#acel12495-bib-0011){ref-type="ref"}; Luo *et al*., [2003](#acel12495-bib-0025){ref-type="ref"}; Hansson *et al*., [2004](#acel12495-bib-0014){ref-type="ref"}). Along these lines, APH‐1α/1β might also be involved in regulating the deposition of Aβ~1--42~ in response to PGI~2~ stimulation.

PGI~2~ is important for regulating the expression of APH‐1α/1β, which is regulated by the PKA/CREB and JNK/c‐Jun signaling pathways and leads to Aβ~1--42~ deposition. Consistent with our observations, Su *et al*. ([2003](#acel12495-bib-0041){ref-type="ref"}) reported that H89 treatment suppressed the production of Aβ in cells that have been stably transfected with human APP bearing a 'Swedish mutation'. They further found that the PKA inhibitor abolishes the mature form of intracellular APP and accumulates the immature form (Su *et al*., [2003](#acel12495-bib-0041){ref-type="ref"}). In addition, Marambaud *et al*. (Marambaud *et al*., [1999](#acel12495-bib-0026){ref-type="ref"}) found that H89 inhibited the production of Aβ~1--40~ and Aβ~1--42~ in HEK293 cells that expressed the APP/PS1 genes. However, these studies were not extended to the expression of β‐ or γ‐secretases. Although the PKA inhibitor has shown similar effects in the suppression of the production of Aβ~1--42~, the role of H89 in Aβ‐induced memory deficit is not conclusively identified (Amini *et al*., [2015](#acel12495-bib-0002){ref-type="ref"}). In addition to the PKA signaling pathway, the JNK/c‐Jun signaling pathways have also been suggested to be involved in Aβ deposition. For example, Jung *et al*. ([2015](#acel12495-bib-0019){ref-type="ref"}) reported that the c‐Jun N‐terminal kinase mediates the effects of auraptene on the production of Aβ by activating γ‐secretase. Shen *et al*. ([2008](#acel12495-bib-0039){ref-type="ref"}) supported this observation by showing that JNK‐dependent activation of γ‐secretase is responsible for Aβ deposition in H~2~O~2~‐stimualted SH‐SY5Y cells. In detail, γ‐secretase as well as presenilin nicastrin is involved in mediating the effects of SP600125 on suppressing the production of Aβ~1--42~ (Kuo *et al*., [2008](#acel12495-bib-0021){ref-type="ref"}; Rahman *et al*., [2012](#acel12495-bib-0037){ref-type="ref"}). More importantly, the inhibition of c‐Jun N‐terminal kinase activation reverses the AD phenotype in APP/PS1 mice (Zhou *et al*., [2015](#acel12495-bib-0055){ref-type="ref"}). Along these lines, our data further found that the PKA/CREB and JNK/c‐Jun pathways are important for Aβ deposition by activating APH‐1α/1β in PGI~2~‐stimulated cells and APP/PS1 mice.

We will focus this discussion on the role of Aβ regulation in the pathogenesis of AD. Interestingly, the expression of APH‐1α/1β was upregulated when we injected (i.c.v.) the CSF of APP/PS1 mice into WT mice. This upregulation was attenuated by the addition of Aβ antibodies. These observations clearly indicate the possible role of CSF‐bound Aβ of APP/PS1 mice in upregulating the expression of APH‐1α/1β. However, previous studies have suggested that the CSF‐bound Aβ~1--42~ level progressively reduced in patients with AD (Mo *et al*., [2015](#acel12495-bib-0029){ref-type="ref"}). These observations indicate that the total level of Aβ~1--42~ in the CSF of APP/PS1 mice might not be critical for upregulating the expression of APH‐1α/1β. As noted by Lopez‐Gonzalez *et al*. ([2015](#acel12495-bib-0024){ref-type="ref"}), the self‐aggregated characteristics of Aβ~1--42~ result in the Aβ~1--42~ oligomers being critical for AD initiation. In agreement with this observation, our data demonstrated that Aβ oligomer injection (i.c.v.) has the ability to stimulate the expression of APH‐1α/1β. More interestingly, NS398 blocked the effects of Aβ oligomers on inducing the expression of APH‐1α/1β. These observations clearly indicated the possible roles of Aβ oligomers in activating COX‐2, which potentially further aggravates AD. In agreement with our hypothesis, Kotilinek *et al*. ([2008](#acel12495-bib-0020){ref-type="ref"}) also suggested that possible cross talk exists between COX‐2 and Aβ.

In conclusion, we elucidated the signaling pathway by which PGI~2~ regulates the expression of APH‐1α/1β in neuron cells of APP/PS1 mice. We found that PGI~2~ treatment upregulates the synthesis of APH‐1α/1β by activating the PKA/CREB and JNK/c‐Jun signaling pathways, which results in Aβ formation in neuronal cells. Aβ injection (i.c.v.) further stimulates the expression of APH‐1α/1β, which potentially contributes to the pathogenesis of AD.

Experimental procedures {#acel12495-sec-0009}
=======================

Reagents {#acel12495-sec-0010}
--------

Unless otherwise specified, all reagents used for the study were described in the supporting information.

Transgenic mice and treatments {#acel12495-sec-0011}
------------------------------

The female wild‐type (WT) or APP/PS1 transgenic mice \[B6C3‐Tg (APPswe, PSEN1dE9) 85Dbo/J (Stock Number: 004462)\] were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Genotyping was performed at 3--4 weeks after birth. In selected experiments, mice at the age of 1 month were treated with NS398 (50 μg kg^−1^ day^−1^) for 5 months before determining the expression of APH‐1α/1β. Each group contains 3 mice. The brains of animals in different groups were collected after anesthesia and perfusion as previously described (Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}).

Cerebrospinal fluid collection {#acel12495-sec-0012}
------------------------------

Cerebral spinal fluid (CSF) was collected according to a published method (Liu *et al*., [2004](#acel12495-bib-0023){ref-type="ref"}) with minor modifications as previously described (Wang *et al*., [2015](#acel12495-bib-0051){ref-type="ref"}; Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}).

Aβ~1--42~ preparation {#acel12495-sec-0013}
---------------------

The methods for preparing Aβ oligomers or fibrils had been described previously (Dahlgren *et al*., [2002](#acel12495-bib-0005){ref-type="ref"}; Moore *et al*., [2002](#acel12495-bib-0030){ref-type="ref"}; Pan *et al*., [2011](#acel12495-bib-0035){ref-type="ref"}). The detailed information was provided in the supportive information.

Intracerebroventricular injection (i.c.v.) {#acel12495-sec-0014}
------------------------------------------

NS398, PGI~2~, Aβ, Aβ antibody, or vehicle (PBS) were injected (i.c.v.) into WT or APP/PS1 transgenic mice as previously described (Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}). Each group contains eight mice. In selected experiments, the WT mice were injected (i.c.v.) with the CSF of APP/PS1 mice. At indicated time intervals, the brains were harvested under anesthesia and perfusion as previously described (Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}).

Organotypic slice culture of brain tissue {#acel12495-sec-0015}
-----------------------------------------

Brain tissue was freshly collected from WT C57BL/6 or APP/PS1 transgenic mice at 6 months of age. Serial sections (400 μ[m]{.smallcaps} thick) were cut using a chopper without fixation. Each group contains eight mice. The tissue sections were immediately cultured in DMEM/high‐glucose medium with 10% FBS. In a separate set of experiments, the tissues were grown in serum‐free medium for an additional 24 h before incubation with PGI~2~ (10 μ[m]{.smallcaps}) or Aβ oligomers (1 μ[m]{.smallcaps}) in the absence or presence of NS398 (10 μ[m]{.smallcaps}), as previously described (Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}). The tissue sections were fixed and immunostained with APH‐1 antibody by IHC staining kit (Invitrogen, Carlsbad, CA, USA).

Luciferase assays and live animal imaging {#acel12495-sec-0016}
-----------------------------------------

The live animal imaging was performed as previously described (Wang *et al*., [2015](#acel12495-bib-0051){ref-type="ref"}; Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}). In brief, the n2a cells that were transfected with APH‐1α/β promoter were preseeded on one side of a cerebral ventricle. PGI~2~ or vehicle (PBS) solutions were then injected (i.c.v.) into the other cerebral ventricle. At different time intervals, the mice were anesthetized and injected (i.c.v.) with luciferin at the side cerebral ventricle, which was preseeded with n2a cells. Each group contains 6 mice. The scan was performed exactly five min after luciferin introduction. All images were analyzed using Bruker *in vivo* imaging systems (MS FX PRO, Carestream, Billerica, MA, USA).

Two‐photon imaging {#acel12495-sec-0017}
------------------

*In vivo* two‐photon recording was performed as previously described (Wang *et al*., [2015](#acel12495-bib-0051){ref-type="ref"}; Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}). In brief, a custom‐built, two‐photon microscope that was based on a chameleon excitation laser operating at 690--1064 nm was used. The laser‐scanning unit was mounted on an upright microscope that was equipped with a water immersion objective (Zeiss; 20×, Beijing, China). The fluorescence was detected using specific antibody staining. The brain slices were stained and scanned before and after the injection (i.c.v.) of PGI~2~ or vehicle (PBS) solutions. Each group contains 6 mice.

Quantitative real‐time PCR (qRT--PCR) {#acel12495-sec-0018}
-------------------------------------

qRT--PCR assays were performed with the MiniOpticon Real‐Time PCR detection system (Bio‐Rad, Hercules, CA, USA) using total RNA and the GoTaq one‐step Real‐Time PCR kit with SYBR green (Promega, Madison, WI, USA) and the appropriate primers as previously described (Wang *et al*., [2010](#acel12495-bib-0044){ref-type="ref"}, [2011b](#acel12495-bib-0046){ref-type="ref"},[c](#acel12495-bib-0047){ref-type="ref"}, [2015](#acel12495-bib-0048){ref-type="ref"},[b](#acel12495-bib-0049){ref-type="ref"}). The GenBank accession number and forward and reverse primers for human or mouse BACE‐1, APH‐1α, APH‐1β, and GAPDH are provided in our previous publications (Wang *et al*., [2014c](#acel12495-bib-0050){ref-type="ref"}; Guan *et al*., [2015a](#acel12495-bib-0012){ref-type="ref"},[b](#acel12495-bib-0013){ref-type="ref"}; Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}). Other primers are shown in Table [2](#acel12495-tbl-0002){ref-type="table-wrap"}, and the gene expression values were normalized to those of GAPDH.

###### 

The primer sequences for α‐, β‐, or γ‐secretases

  ---------------------------------------------------------
  Gene symbol   GenBank number   Sequences
  ------------- ---------------- --------------------------
  ADAM‐10       NM_007399        F‐ATTGCTGCTTCGATGCCAAC\
                                 R‐GCACCGCATGAAAACATCAC

  PS1           NM_008943        F‐GCTTGTAGGCGCCTTTAGTG\
                                 R‐CATCTGGGCATTCTGGAAGT

  PS2           NM_011183        F‐AAGAACGGGCAGCTCATCTA\
                                 R‐TCCAGACAGCCAGGAAGAGT

  NCT           NM_021607        F‐TGTGCAGTGCCCAAATGATG\
                                 R‐GGCCACATTCCAGAAAAAGGAC

  PEN2          NM_025498        F‐ACTGAAAACTGCGGCATCTC\
                                 R‐ATTGGGGCAGATGGGAAATG
  ---------------------------------------------------------

John Wiley & Sons, Ltd

Immunostaining {#acel12495-sec-0019}
--------------

Human SH‐SY5Y and mouse n2a cells were immunostained as previously described (Wang *et al*., [2011c](#acel12495-bib-0047){ref-type="ref"}). In brief, cells were permeabilized with 0.1% Triton X‐100 for 1 min at 4 °C, fixed with 4% paraformaldehyde for 10 min at 37 °C, washed with PBS (−), and incubated in buffer containing 1% BSA/PBS (−) for 10 min at room temperature. Cells were then incubated with a rabbit antibody to APH‐1 for 60 min at room temperature, washed with 1% BSA/PBS (−), and incubated in buffer containing Alexa Fluor 488‐labeled goat anti‐rabbit IgG for 60 min at room temperature. The cells were then washed five times with 1% BSA/PBS (−) before incubation in DAPI solution for five min. Finally, the cells were washed five times with 1% BSA/PBS (−) and once with deionized water before observation under confocal microscopy (Leica, TCS‐SP8, Liaoning, Shenyang, China).

Human brain samples {#acel12495-sec-0020}
-------------------

Human brain samples were obtained from New York Brain Bank, serial numbers P535‐00 (normal), T4339, T4304, and 235‐95 (patients with AD). Another two normal brain samples were obtained from Fengtian Hospital of China (the patients are 59‐ and 63‐year‐old men who were diagnosed as cerebral edema, and the normal tissues are collected surrounding the tissues of cerebral edema).

The information for immunohistochemistry (IHC), cell culture, Western blot analysis, measurement of the Aβ~1--42~ or PGI~2~ concentration in the culture medium or the brain of mice, Transfection and Animal committee, was described in the supporting information.

Statistical analysis {#acel12495-sec-0021}
--------------------

All data are represented as the mean ± SE of at least three independent experiments. The statistical significance of the differences between the means was determined using a Student\'s *t*‐test or a one‐way ANOVA, where appropriate. If the means were found to be significantly different, multiple pairwise comparisons were performed using the Tukey\'s test (Wang *et al*., [2015](#acel12495-bib-0048){ref-type="ref"},[c](#acel12495-bib-0050){ref-type="ref"}; Guan *et al*., [2015a](#acel12495-bib-0012){ref-type="ref"},[b](#acel12495-bib-0013){ref-type="ref"}; Yu *et al*., [2015](#acel12495-bib-0054){ref-type="ref"}).
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